Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema ; volume:38 ; number:18 ; day:11 ; month:10 ; year:2024 ; pages:3569-3577 ; date:12.2024
Eye ; 38, Heft 18 (11.10.2024), 3569-3577, 12.2024
- Creator
-
Borchert, Grace A.
Kiire, Christine A.
Stone, Niamh M.
Akil, Handan
Gkika, Theodora
Fischer, M. Dominik
Xue, Kanmin
Cehajic-Kapetanovic, Jasmina
MacLaren, Robert E.
Charbel Issa, Peter
Downes, Susan M.
De Silva, Samantha R.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41433-024-03364-y
- URN
-
urn:nbn:de:101:1-2502192124546.344736198130
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Borchert, Grace A.
- Kiire, Christine A.
- Stone, Niamh M.
- Akil, Handan
- Gkika, Theodora
- Fischer, M. Dominik
- Xue, Kanmin
- Cehajic-Kapetanovic, Jasmina
- MacLaren, Robert E.
- Charbel Issa, Peter
- Downes, Susan M.
- De Silva, Samantha R.
- SpringerLink (Online service)
Other Objects (12)
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept
The impact of Vitreo-Macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema
Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
Influence of macular oedema on the measurement of macular pigment optical density
The architecture of macular neovascularizations predicts treatment responses to anti-VEGF therapy in neovascular AMD
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Hyperreflective material evolution patterns during long term anti-VEGF therapy in neovascular age-related macular degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists
Pipeline therapies for neovascular age related macular degeneration
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept
The impact of Vitreo-Macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema
Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
Influence of macular oedema on the measurement of macular pigment optical density
The architecture of macular neovascularizations predicts treatment responses to anti-VEGF therapy in neovascular AMD
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Hyperreflective material evolution patterns during long term anti-VEGF therapy in neovascular age-related macular degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists
Pipeline therapies for neovascular age related macular degeneration
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept
The impact of Vitreo-Macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema
Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
Influence of macular oedema on the measurement of macular pigment optical density
The architecture of macular neovascularizations predicts treatment responses to anti-VEGF therapy in neovascular AMD
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Hyperreflective material evolution patterns during long term anti-VEGF therapy in neovascular age-related macular degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists